| 1. |
SERMs: a major therapeutic advance |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1375,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 2. |
A 3-year project to accelerate the development of a safe and effective rotavirus vaccine for the developing world has been announced |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1375,
2003,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 3. |
Meloxicam frequently prescribed in rheumatic disorders |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1375,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 4. |
Resource use, costs associated with glaucoma in the US |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1375,
2003,
Page 5-5
C Johnston,
Preview
|
|
摘要:
Although studies in the past have looked at the total societal cost of treating glaucoma, the third leading cause of blindness worldwide, none to date has examined the cost of treating the disease according to its severity. However, the results of a study presented at the 2002 annual meeting of the American Academy of Ophthalmology held in Orlando, Florida, US, suggest that the annual direct cost of treating the condition is more than four times greater at the most severe stage of the disease than it is at the earliest stage. Moreover, a second study has shown that a significant percentage of patients with glaucoma do not take their medications as indicated because of financial concerns.
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 5. |
Epoetin alfa helps improve QOL in renal anaemia |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1375,
2003,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 6. |
Atazanavir: potent antiviral activity against HIV |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1375,
2003,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 7. |
Onercept promising in Crohn's disease |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1375,
2003,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 8. |
Ximelagatran reduces risk of VTE |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1375,
2003,
Page 9-10
RM Poole,
Preview
|
|
摘要:
The oral anticoagulant ximelagatran ['Exanta'] reduced the risk of venous thromboembolism (VTE) in two phase III studies presented at the 44th Annual Meeting of the American Society of Hematology (ASH) [Philadelphia, US; December 2002]. The first study, EXULT A, showed that treatment with ximelagatran reduced the risk of VTE following total knee replacement (TKR) surgery, compared with warfarin. In the second study, THRIVE III, continuing treatment with ximelagatran for 18 months after completion of a standard 6-month course of anticoagulant therapy reduced the risk of recurrence in patients with a history of VTE by 84%, compared with placebo.
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 9. |
uPA-anthrax toxin: promising antitumour activity |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1375,
2003,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 10. |
ACE inhibitors preferable in hypertension? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1375,
2003,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
首页
